Turn Biotechnologies vs Eikon Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails that transiently reprogram aged cells to youthful epigenetic states without altering DNA.
About
Turn Biotechnologies is a longevity company using modified mRNA cocktails to transiently reprogram aged cells back toward a youthful epigenetic state — without permanently altering DNA sequences. The company has raised $29 million in Series A financing and acquired ARMMs (Arrestin Domain-Containing Protein 1 Mediated Microvesicle) technology in March 2025 to significantly upgrade the delivery capability of its mRNA reprogramming platform.
Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates new drug discovery data category.
About
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution microscopy platform that tracks individual protein molecules in living cells in real time. Unlike computational drug discovery approaches that model proteins in isolation, Eikon's platform observes how proteins actually behave within the complex, dynamic environment of living cells — generating a new category of drug discovery data that no other method can produce.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.